EE200200399A - Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon - Google Patents

Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon

Info

Publication number
EE200200399A
EE200200399A EEP200200399A EEP200200399A EE200200399A EE 200200399 A EE200200399 A EE 200200399A EE P200200399 A EEP200200399 A EE P200200399A EE P200200399 A EEP200200399 A EE P200200399A EE 200200399 A EE200200399 A EE 200200399A
Authority
EE
Estonia
Prior art keywords
preparation
pyrrole
lipid
pharmaceutical composition
composition containing
Prior art date
Application number
EEP200200399A
Other languages
English (en)
Inventor
Bhushan Lohray Braj
Bhushan Lohray Vidya
Kumar Gajubhai Barot Vijay
Original Assignee
Cadila Healthcare Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd. filed Critical Cadila Healthcare Ltd.
Publication of EE200200399A publication Critical patent/EE200200399A/et
Publication of EE05082B1 publication Critical patent/EE05082B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
EEP200200399A 2000-01-19 2001-01-17 Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon EE05082B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN57MU2000 2000-01-19
PCT/IN2001/000005 WO2001053257A2 (en) 2000-01-19 2001-01-17 Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
EE200200399A true EE200200399A (et) 2003-10-15
EE05082B1 EE05082B1 (et) 2008-10-15

Family

ID=11097206

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200399A EE05082B1 (et) 2000-01-19 2001-01-17 Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon

Country Status (30)

Country Link
EP (1) EP1250323B1 (et)
JP (2) JP4213385B2 (et)
KR (1) KR100649304B1 (et)
CN (1) CN1266129C (et)
AP (1) AP1522A (et)
AU (1) AU779332B2 (et)
BG (1) BG65370B1 (et)
BR (1) BRPI0108024B8 (et)
CA (1) CA2397828C (et)
CZ (1) CZ304346B6 (et)
DK (1) DK1250323T3 (et)
DZ (1) DZ3279A1 (et)
EA (1) EA007959B1 (et)
EE (1) EE05082B1 (et)
ES (1) ES2449194T3 (et)
HR (1) HRP20020643B1 (et)
HU (1) HU230609B1 (et)
IL (2) IL150821A0 (et)
ME (1) MEP32408A (et)
MX (1) MXPA02007080A (et)
NO (1) NO324689B1 (et)
NZ (1) NZ520402A (et)
OA (1) OA12162A (et)
PL (1) PL222486B1 (et)
PT (1) PT1250323E (et)
SK (1) SK287294B6 (et)
UA (1) UA73546C2 (et)
WO (1) WO2001053257A2 (et)
YU (1) YU54902A (et)
ZA (1) ZA200205789B (et)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
BR9812770A (pt) 1997-10-27 2000-12-12 Reddy Research Foundation Compostos bicìclicos, processo para seu preparo e composições farmacêuticas contendo os mesmos
MXPA00004036A (es) 1997-10-27 2006-05-24 Reddys Lab Ltd Dr Compuestos triciclicos novedosos y su uso en medicina; proceso para su preparacion y composiciones farmaceuticas que los contienen..
JP2002528535A (ja) 1998-10-29 2002-09-03 ドクター・レディーズ・リサーチ・ファウンデーション 新規抗糖尿病剤製造の改良方法
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
EP1386913B1 (en) * 2001-04-19 2008-07-16 Dainippon Sumitomo Pharma Co., Ltd. Pyrrole derivative
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
DE60333762D1 (de) * 2002-08-23 2010-09-23 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
DE10305089A1 (de) * 2003-02-07 2004-08-26 Merckle Gmbh Neue heteroarylsubstituierte Acetonderivate als Hemmstoffe der Phospholiphase A2
KR101633720B1 (ko) 2011-01-31 2016-06-27 카딜라 핼쓰캐어 리미티드 지방이상증의 치료
WO2012144661A1 (en) 2011-04-20 2012-10-26 Shionogi & Co., Ltd. Aromatic heterocyclic derivative having trpv4-inhibiting activity
UA114360C2 (uk) 2013-04-22 2017-05-25 Каділа Хелткере Лімітед Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (et) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (et) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
MX382765B (es) 2016-12-09 2025-03-13 Zydus Lifesciences Ltd Tratamiento para la colangitis biliar primaria.
CN108191732B (zh) * 2018-02-23 2020-11-24 贝利化学（张家港）有限公司 一种n-甲基吡咯的合成方法
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD86826A (et) *
US3534061A (en) * 1967-12-04 1970-10-13 Parke Davis & Co N-(alpha-(p-methoxyphenyl)-beta-nitrostyryl)-phenoxyalkyl pyrroles
DD88826B1 (de) * 1971-05-14 1973-11-20 Ljudmil Petkow Schaltungsanordnung zur Ansteuerung eines Wechselrichters für den definierten Antrieb eines Wechselstrommotors
US3980089A (en) * 1972-04-21 1976-09-14 International Flavors & Fragrances Inc. Novel heterocyclic flavoring compositions and processes
ZA781173B (en) * 1977-03-21 1979-02-28 Zoecon Corp Novel compositions
US4229352A (en) * 1979-08-13 1980-10-21 Zoecon Corporation Benzylpyrrolylmethyl esters of cyclopropane carboxylic acids
US4232038A (en) * 1979-08-31 1980-11-04 Syntex (U.S.A.) Inc. 5-Alkylsulfinylbenzoyl- and 5-alkylsulfonylbenzoyl-1,2-dihydro-3H-pyrrolo[1,]pyrrole-1-carboxylic acids
US4224330A (en) * 1979-09-13 1980-09-23 Zoecon Corporation Esters and thiolesters of benzothienyl acids
US4235777A (en) * 1979-11-19 1980-11-25 Zoecon Corporation Benzylpyrrolylmethyl esters of 3-(1,2-dibromo-2,2-dichloroethyl)-2,2-dimethylcyclopropanecarboxylic acid
US4410534A (en) * 1979-12-26 1983-10-18 Syntex (U.S.A.) Inc. 3-Substituted-5,6,7,8-tetrahydropyrrolo[1,2-a]-pyridine-and 6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]-azepine carboxylic acid derivatives useful as blood platelet aggregation inhibitors
US4344943A (en) * 1980-06-09 1982-08-17 Syntex (U.S.A.) Inc. 6-Chloro- or 6-bromo-1,2-dihydro-3H-pyrrolo[1,2-a]-pyrrole-1-carboxylic acids and derivatives thereof
US4560699A (en) * 1983-01-17 1985-12-24 Syntex (U.S.A.) Inc. 5-(4-Vinylbenzoyl)-1,2-dihydro-3H-pyrrolo-[1,2-a]-pyrrole-1-carboxylic acids and derivatives thereof and use as analgesics and anti-inflammatories
US4505920A (en) * 1983-03-03 1985-03-19 Usv Pharmaceutical Corporation Certain N-substituted-4-aryl-3,5-pyridine dicarboxylates and their antihypertensive use
BG43855A3 (bg) * 1983-06-17 1988-08-15 Ciba - Geigy Ag Фунгицидно средство и метод за борба срещу фитопатогенни гъбички
US4546099A (en) * 1983-07-22 1985-10-08 Ciba-Geigy Corporation N-Aminomethyl-3-phenyl-4-cyanopyrrole derivatives, compositions and use thereof as microbicides
FR2563229B1 (fr) * 1984-04-20 1986-07-18 Commissariat Energie Atomique Materiau electrochrome organique, son procede de fabrication et son application a l'affichage
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
CZ1095A3 (en) * 1992-07-03 1995-10-18 Smithkline Beecham Plc Heterocyclic compounds, process of their preparation, their use for the preparation of a pharmaceutical preparation and the pharmaceutical composition containing thereof
EP0670720A1 (en) * 1992-11-27 1995-09-13 The Wellcome Foundation Limited Enzyme inhibitors
GB9225386D0 (en) * 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5418242A (en) * 1993-05-18 1995-05-23 Laboratoires Upsa Piperidinylthioindole derivatives, their methods of preparation and pharmaceutical compositions in which they are present, useful especially as analgesics
US5387613A (en) * 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) * 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
BR9608040B1 (pt) * 1995-04-28 2010-02-23 composto taxàide pentacÍclico.
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CA2258949C (en) * 1996-07-01 2008-05-06 Reddy-Cheminor, Inc. Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
JPH11505006A (ja) * 1996-12-24 1999-05-11 デウー・モーター・シーオー・エルティーディー 内燃機関の排気ガス再循環弁装置
ES2200248T3 (es) * 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
MXPA00004036A (es) * 1997-10-27 2006-05-24 Reddys Lab Ltd Dr Compuestos triciclicos novedosos y su uso en medicina; proceso para su preparacion y composiciones farmaceuticas que los contienen..
CN1280574A (zh) * 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1073643B1 (en) * 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002507543A (ja) * 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
US6747188B2 (en) * 1998-10-01 2004-06-08 North Carolina State University Transgenic plants expressing a mutant geminivirus AL3/C3 coding sequence
WO2000023451A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use

Also Published As

Publication number Publication date
BRPI0108024B8 (pt) 2021-05-25
DZ3279A1 (fr) 2001-07-26
MXPA02007080A (es) 2003-09-25
UA73546C2 (en) 2005-08-15
CA2397828A1 (en) 2001-07-26
WO2001053257A2 (en) 2001-07-26
KR20020075888A (ko) 2002-10-07
EP1250323B1 (en) 2014-01-01
KR100649304B1 (ko) 2006-11-24
CZ304346B6 (cs) 2014-03-19
AP1522A (en) 2005-12-22
NO20023400L (no) 2002-09-09
OA12162A (en) 2006-05-08
AU779332B2 (en) 2005-01-20
SK287294B6 (sk) 2010-05-07
YU54902A (sh) 2005-06-10
BRPI0108024B1 (pt) 2015-09-15
PL222486B1 (pl) 2016-08-31
JP2008308504A (ja) 2008-12-25
SK10592002A3 (sk) 2003-03-04
NZ520402A (en) 2006-04-28
JP5144421B2 (ja) 2013-02-13
BG106932A (en) 2004-01-30
ZA200205789B (en) 2003-10-02
JP2003520268A (ja) 2003-07-02
AU4872801A (en) 2001-07-31
EA007959B1 (ru) 2007-02-27
JP4213385B2 (ja) 2009-01-21
BG65370B1 (bg) 2008-04-30
EP1250323A2 (en) 2002-10-23
HRP20020643B1 (hr) 2015-04-24
CA2397828C (en) 2007-09-04
AP2002002575A0 (en) 2002-09-30
IL150821A0 (en) 2003-02-12
HUP0301811A3 (en) 2006-04-28
HK1058039A1 (en) 2004-04-30
NO324689B1 (no) 2007-12-03
HU230609B1 (hu) 2017-03-28
ES2449194T3 (es) 2014-03-18
MEP32408A (en) 2010-10-10
IL150821A (en) 2008-12-29
HRP20020643A2 (en) 2005-10-31
PL365379A1 (en) 2005-01-10
WO2001053257A3 (en) 2002-06-27
BR0108024A (pt) 2003-03-11
EE05082B1 (et) 2008-10-15
DK1250323T3 (da) 2014-02-03
PT1250323E (pt) 2014-04-07
EA200200774A1 (ru) 2003-02-27
CN1266129C (zh) 2006-07-26
HUP0301811A2 (hu) 2003-09-29
CN1449381A (zh) 2003-10-15
NO20023400D0 (no) 2002-07-15

Similar Documents

Publication Publication Date Title
EE200200399A (et) Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
EE200100318A (et) Kinoliini derivaat, selle ühendi kasutamine ravimina, seda sisaldav farmatseutiline kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
NO20020208L (no) Flytende sammensetninger for oral administrasjon
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200200046A (et) 8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
EE200300587A (et) Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine
EE04997B1 (et) Loteprednooli ja antihistamiinseid aineid sisaldav farmatseutiline kompositsioon, neid aineid sisaldav ravim, meetod selle ravimi valmistamiseks ja nende ainete kombinatsiooni kasutamine
AU2000276362A1 (en) Composition for the treatment of diabetes
NO20014738L (no) Tolperisonholdig farmasöytisk preparat for oral administrering
EE200300488A (et) Lipiiditaset alandava toimega bifenüülkarboksamiidühend, meetod selle valmistamiseks ning seda sisaldav ravimkompositsioon
HUP0400115A3 (en) Pharmaceutical composition for the intramuscular administration of fulvestrant
ZA200203077B (en) Ciclesonide contained pharmaceutical composition for application to mucosa.
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
EE200100662A (et) Hüübimistegurit pärssiv ühend, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaatning raviotstarbeline kasutamine
EE200300398A (et) Isoksasoliini derivaat, selle saamine ja kasutamine depresioonivastase ravimi valmistamiseks ning seda sisaldav ravimkompositsioon
EE200200109A (et) Asendatud 3-fenüül-5-alkoksü-1,3,4-oksdiasool-2-oon, selle valmistamine ja kasutamine lipaasi inhibiitorina ning seda sisaldav ravim
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
EE05050B1 (et) Loteprednooli ja β2-adrenoretseptori agonistide kombinatsioon, selle kasutamine, seda kombinatsiooni sisaldav farmatseutiline preparaat ja ravim ning meetod seda kombinatsiooni sisaldava ravimivalmistamiseks
AU5072000A (en) Pharmaceutical composition for nasally administering water-soluble active substances
EE200200528A (et) 2-fenüülpüran-4-ooni derivaat, meetod selle valmistamiseks, seda sisaldav farmatseutiline kompositsioon ning ühendi ja kompositsiooni raviotstarbeline kasutamine
EE04611B1 (et) Tsinnamoüülaminoalküül-asendatud benseensulfoonamiidi derivaat, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning kasutamine ravimina
AU2001260083A1 (en) New pharmaceutical composition and the process for its preparation

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20180117